Edition:
India

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

0.65USD
16 Aug 2019
Change (% chg)

$-0.00 (-0.08%)
Prev Close
$0.65
Open
$0.65
Day's High
$0.67
Day's Low
$0.64
Volume
30,156
Avg. Vol
84,897
52-wk High
$2.29
52-wk Low
$0.60

Latest Key Developments (Source: Significant Developments)

CTI Biopharma Announces Outcome From End-Of-Phase-2A Meeting With FDA Regarding Pacritinib
Thursday, 18 Jul 2019 

July 18 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA ANNOUNCES OUTCOME FROM END-OF-PHASE-2A MEETING WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA) REGARDING PACRITINIB FOR TREATMENT OF MYELOFIBROSIS.CTI BIOPHARMA CORP - COMPANY PLANS TO INITIATE PHASE 3 PACIFICA STUDY IN Q3 OF 2019.CTI BIOPHARMA CORP - PLANS TO ADVANCE PACRITINIB 200 MG TWICE-DAILY (BID) DOSE TO PHASE 3 FOR PATIENTS WITH SEVERE THROMBOCYTOPENIA.CTI BIOPHARMA CORP - COMPANY EXPECTS TOPLINE SAFETY AND EFFICACY RESULTS FROM PHASE 2 PORTION OF PAC203 STUDY IN Q3 OF 2019.CTI BIOPHARMA CORP - TARGETING PRESENTATION OF PHASE 2 RESULTS FOR PAC203 STUDY AT A SCIENTIFIC CONFERENCE BEFORE END OF 2019.CTI BIOPHARMA CORP - CURRENTLY AMENDING PROTOCOL FOR ONGOING PHASE 2 PAC203 STUDY TO INCLUDE NEW PACIFICA PHASE 3 PORTION.  Full Article

CTI Biopharma Reports First Quarter 2019 Financial Results
Friday, 3 May 2019 

May 2 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.19.Q1 REVENUE $600,000 VERSUS $10.8 MILLION.EXPECTS CURRENT CASH WILL ENABLE IT TO FUND OPERATING THROUGH Q2 OF 2020..  Full Article

CTI Biopharma Enters Into A Termination Agreement With Les Laboratoires Servier & Institut De Recherches Internationales Servier
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP - ENTERED INTO A TERMINATION AGREEMENT WITH LES LABORATOIRES SERVIER AND INSTITUT DE RECHERCHES INTERNATIONALES SERVIER.CTI BIOPHARMA CORP - TERMINATION AGREEMENT TERMINATES AMENDED AND RESTATED EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT, DATED AS OF APRIL 21, 2017.CTI BIOPHARMA CORP - COMPANY WILL CONTINUE TO BE RESPONSIBLE FOR NON-U.S. PHARMACOVIGILANCE FOR PIXUVRI.CTI BIOPHARMA CORP - COMPANY WILL CONTINUE TO BE RESPONSIBLE FOR SUBMISSION OF A MARKETING AUTHORIZATION APPLICATION FOR PIXUVRI.CTI BIOPHARMA CORP - COMPANY WILL CONTINUE TO BE RESPONSIBLE FOR WIND DOWN OF PIX306 CLINICAL TRIAL DURING A TRANSITION PERIOD.CTI BIOPHARMA CORP - SERVIER AGREED TO REIMBURSE COMPANY EUR620,000 FOR COSTS TO BE INCURRED IN CONNECTION WITH TRANSITION PERIOD ACTIVITIES.  Full Article

CTI Biopharma Receives $10 Million Milestone Payment For Trisenox
Monday, 11 Feb 2019 

Feb 11 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA RECEIVES $10 MILLION MILESTONE PAYMENT FOR TRISENOX®.CTI BIOPHARMA CORP - RECEIVED $10 MILLION MILESTONE PAYMENT FROM TEVA PHARMACEUTICAL INDUSTRIES RELATED TO ACHIEVEMENT OF SALES MILESTONES FOR TRISENOX.  Full Article

CTI Biopharma Announces Completion Of Enrollment In The Phase 2 PAC203 Study Of Pacritinib
Friday, 28 Dec 2018 

Dec 28 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 2 PAC203 STUDY OF PACRITINIB.CTI BIOPHARMA CORP - OPTIMAL DOSE DETERMINATION FROM PAC203 STUDY EXPECTED IN MID-2019 WITH TOPLINE DATA EXPECTED IN Q3 OF 2019.CTI BIOPHARMA CORP - PLANNED INTERIM SAFETY REVIEW BY AN INDEPENDENT DATA MONITORING COMMITTEE IS SCHEDULED TO OCCUR IN Q1 OF 2019.  Full Article

CTI Biopharma Provides Program Update Following Regulatory Feedback On Pacritinib Development From The European Medicines Agency
Tuesday, 27 Nov 2018 

Nov 26 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA PROVIDES PROGRAM UPDATE FOLLOWING REGULATORY FEEDBACK ON PACRITINIB DEVELOPMENT FROM THE EUROPEAN MEDICINES AGENCY.CTI BIOPHARMA CORP - EUROPEAN REGULATORY OPINION ON MARKETING AUTHORIZATION APPLICATION (MAA) FOR PACRITINIB NOW EXPECTED IN Q1 OF 2019.CTI BIOPHARMA CORP - RECEIVED A SECOND ROUND OF QUESTIONS RELATED TO DAY 180 LIST OF OUTSTANDING ISSUES FROM EUROPEAN MEDICINES AGENCY (EMA).CTI BIOPHARMA CORP - PLANS TO SUBMIT RESPONSES TO EMA, WHICH WILL INCLUDE DATA FROM ONGOING OPEN LABEL PAC203 TRIAL, BY END OF YEAR.  Full Article

CTI Biopharma Corp Updates on Use For Pacritinib
Friday, 25 May 2018 

May 25 (Reuters) - CTI Biopharma Corp ::CTI BIOPHARMA CORP - ON MAY 24, SUBMITTED ITS RESPONSES TO D120 LOQ BY COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE FOR PACRITINIB - SEC FILING.CTI BIOPHARMA - EMA'S FEB 2018 FINAL GCP INSPECTION REPORT CONCLUDED PERSIST-2 CLINICAL TRIAL OF PACRITINIB GENERALLY CONDUCTED IN COMPLIANCE WITH GCP.  Full Article

CTI Biopharma Q4 Loss Per Share $0.33
Thursday, 8 Mar 2018 

March 7 (Reuters) - Cti Biopharma Corp ::CTI BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.33.TOTAL REVENUES FOR Q4 WERE $0.46 MILLION COMPARED TO $9.1 MILLION.  Full Article

Growth Equity Opportunities Fund Reports 6.0 Pct Stake In CTI Biopharma
Wednesday, 21 Feb 2018 

Feb 20 (Reuters) - Growth Equity Opportunities Fund V Llc : :GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 6.0 PERCENT STAKE IN CTI BIOPHARMA CORP AS OF FEB 8 - SEC FILING.GROWTH EQUITY OPPORTUNITIES FUND V LLC SAYS ACQUIRED CTI BIOPHARMA CORP SHARES FOR INVESTMENT PURPOSES.  Full Article

CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
Tuesday, 13 Feb 2018 

Feb 13 (Reuters) - CTI BioPharma <>::CTI BIOPHARMA ANNOUNCES CLOSING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK.  Full Article